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Abstract
The hormone relaxin (RLX) is produced by the heart and has beneficial actions on the cardiovascular system. We previously
demonstrated that RLX stimulates mouse neonatal cardiomyocyte growth, suggesting its involvement in endogenous
mechanisms of myocardial histogenesis and regeneration. In the present study, we extended the experimentation by
evaluating the effects of RLX on primary cultures of neonatal cardiac stromal cells. RLX inhibited TGF-b1-induced fibroblast-
myofibroblast transition, as judged by its ability to down-regulate a-smooth muscle actin and type I collagen expression. We
also found that the hormone up-regulated metalloprotease (MMP)-2 and MMP-9 expression and downregulated the tissue
inhibitor of metalloproteinases (TIMP)-2 in TGF-b1-stimulated cells. Interestingly, the effects of RLX on cardiac fibroblasts
involved the activation of Notch-1 pathway. Indeed, Notch-1 expression was significantly decreased in TGF-b1-
stimulatedfibroblasts as compared to the unstimulated controls; this reduction was prevented by the addition of RLX to
TGF-b1-stimulated cells. Moreover, pharmacological inhibition of endogenous Notch-1 signaling by N-3,5-difluorophenyl
acetyl-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT), a c-secretase specific inhibitor, as well as the silencing of
Notch-1 ligand, Jagged-1, potentiated TGF-b1-induced myofibroblast differentiation and abrogated the inhibitory effects of
RLX. Interestingly, RLX and Notch-1 exerted their inhibitory effects by interfering with TGF-b1 signaling, since the addition of
RLX to TGF-b1-stimulated cells caused a significant decrease in Smad3 phosphorylation, a typical downstream event of TGF-
b1 receptor activation, while the treatment with a prevented this effect. These data suggest that Notch signaling can down-
regulate TGF-b1/Smad3-induced fibroblast-myofibroblast transition and that RLX could exert its well known anti-fibrotic
action through the up-regulation of this pathway. In conclusion, the results of the present study beside supporting the role
of RLX in the field of cardiac fibrosis, provide novel experimental evidence on the molecular mechanisms underlying its
effects.
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Introduction
Relaxin (RLX) is a polypeptide hormone with well-recognized
antifibrotic properties [1,2]. Although first described as a
reproductive hormone causing an increase in uterine cervix
collagen solubility and softening of the pubic symphysis during
pregnancy [3], evidence is accumulating that it is also able to
regulate extracellular matrix (ECM) remodeling in organs and
tissues other than the reproductive system, such as the heart, liver,
kidney, and lung [1,2,4–7]. Indeed, RLX knock-out (KO) mice
have been shown to develop age-associated pulmonary, renal and
left ventricular fibrosis, which can be reversed by the administra-
tion of exogenous RLX [8–11]. Moreover, the treatment with
RLX or RXFP1 (RLX receptor) agonists induces a collagen-
degrading phenotype in a variety of experimental settings,
including bleomycin-induced lung and peri-bronchiolar fibrosis
[12,13] and prevents fibrosis associated with skeletal muscle injury
[14,15]. Several in vitro and in vivo studies have reported that the
effects of RLX on collagen deposition are mainly mediated by its
ability to inhibit TGF-b1-induced fibroblast-myofibroblast transi-
tion [16–19] and stimulate the expression and release of ECM-
degrading enzymes by a large number of cells. The fact that RLX
has no effects on basal collagen expression [19] have sparkled
interest in the therapeutic potential of this hormone as an anti-
fibrotic agent, so that clinical trials have been carried out to test its
effectiveness in the treatment of diseases characterized by a
prominent component of fibrosis [20–23].
Notch-1 is part of a highly conserved signaling pathway between
adjacent cells, which involves the expression of receptors (Notch-
1/4) and cognate transmembrane ligands (Jagged-1/2) that
mediate key cell fate decisions during development and in
differentiated tissues. Upon ligand binding, the Notch intracellular
domain (NICD) is released by proteolytic cleavage operated by c-
secretase complex, migrates into the nucleus and interacts with
transcriptional repressors [24]. Of interest, Notch signaling has
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been recently shown to be involved in tissue fibrosis: depending on
cells and stimuli, it can positively or negatively influence the
switching of fibroblasts into myofibroblasts [25–28]. In particular,
over-expression of Notch-1 has been shown to facilitate lung
fibroblast transition into myofibroblasts [27]. On the other hand, it
has been reported that Notch-1 can inhibit the conversion of
hepatic stellate cells and 10T1/2 fibroblasts into myofibroblasts
[26], that Jagged-1 over-expressing fibroblasts are refractory to the
profibrotic effects of TGF-b1- [29], and that inhibition of Notch
signaling by a highly active c-secretase inhibitor N-[N-(3,5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT)
promotes cardiac fibroblast-myofibroblast transition [25]. Along
this line of evidence, it has been recently demonstrated that TGF-
b1 limits Notch-1 activation in mouse fibroblasts by inducing the
expression of ADAM12 [30,31], a member of metalloprotease-
disintegrin family, which is capable of cleaving Notch ectodomain
after ligand-receptor interaction [32,33]. This finding suggests a
functional antagonism between TGF-b1 and Notch-1 signaling.
On the basis of these observations, the aim of this study was to
investigate the role of Notch-1 signaling in primary cultures of
mouse cardiac stromal cells and NIH/3T3 fibroblasts and to
evaluate whether RLX could exert its anti-fibrotic effects through
the down-regulation of fibroblast-myofibroblast transition operat-
ed by Notch-1 signaling.
Materials and Methods
Ethics Statements
Animal handling and use complied with the European
Community guidelines for animal care (DL 116/92, application
of the European Communities Council Directive of 24 November
1986; 86/609/EEC) and were approved by the Committee for
Animal Care and Experimental Use of the University of Florence.
The ethical policy of the University of Florence conforms to the
Guide for the care and use of laboratory animals of the U.S.
National Institutes of Health (NIH Publication No. 85–23, revised
1996; University of Florence assurance No. A5278-01). The
protocols were communicated to local authorities and to Italian
Ministry of the Health; according to the Italian law (Art.7/D.lgs
116/92) such procedure doesn’t require Ministry authorization.
The animals had free access to food and water and were housed
on a 12 h light/dark cycle at 22uC room temperature. The
experiments were designed to minimize pain and the number of
animals used. Sacrifice was carried out by decapitation.
Cell Culture and Treatments
Murine fibroblastic NIH/3T3 cells, obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA), were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicillin
(100 U/ml) and streptomycin (100 U/ml) (Sigma, Milan, Italy) at
37uC in a humidified atmosphere of 5% CO2.
Primary cultures of mouse cardiac stromal cells were prepared
from hearts of 1-day old newborn CD1 albino mice (Harlan,
Correzzana, Italy) according to Formigli et al. [34], with modifi-
cations. Briefly, hearts were quickly excised, the atria were cut-off
and the ventricles minced and digested at 37uC for 45 min in
calcium-free HEPES-buffered Hanks’ solution, pH 7.4, containing
100 g/ml type II collagenase (Invitrogen, Carlsbad, CA, USA).
The tissue lysate was filtered through a 70 mm cell strainer
(Millipore, Billerica, MA, USA) and pre-plated for 1 h. Cardio-
myocyte-rich cell suspension was discarded while the cells
adherent to the culture plate, mainly composed by stromal cells,
were cultured in DMEM supplemented with 20% FBS, penicillin
(100 U/ml) and streptomycin (100 U/ml) (Sigma) at 37uC in a
humidified atmosphere of 5% CO2. When the cultures reached
about 80% confluence, the adherent cells were detached with
0.05% trypsin-0.03% EDTA (Invitrogen) for 5 min at 37uC,
washed with PBS, re-suspended in DMEM and plated on tissue
culture dishes (P1) to be used for the experiments. Aliquots of cells
at P1 culture passage were seeded on glass coverslips and assayed
for vimentin immunophenotype by confocal microscopy to
confirm their stromal nature and to test the degree of purity of
the cell cultures, which usually was 92–98%.
Both NIH/3T3 fibroblasts and primary cardiac stromal cells
(P1) were induced to transform into myofibroblasts in DMEM
containing 2% FBS for different times (24 h, 48 h, 72 h, 5 days) in
the absence (control) or presence of 2 ng/ml human TGF-b1
(PeproTech, Inc., Rocky Hill, NJ, USA). In some experiments
human recombinant H2 RLX (kindly provided by Prof. Mario
Bigazzi, Foundation for the Study of Relaxin in Cardiovascular
and Other Diseases, Prosperius Institute, Florence, Italy) was
added to the culture medium at a 100 ng/ml final concentration.
This RLX concentration was similar to that used previously to
Figure 1. Characterization and expression of RLX receptor on primary neonatal cardiac fibroblasts. A) Representative contrast phase
microscopy images of first passage neonatal murine neonatal cardiac fibroblasts. B) Representative superimposed differential interference contrast
(DIC) and confocal immunofluorescence images of neonatal cardiac fibroblasts immunostained with antibodies against vimentin (green). Nuclei are
counterstained in red with propidium iodide. C) Expression of Relaxin family peptide receptor 1 (RXFP1) in neonatal cardiac fibroblasts and NIH/3T3 at
mRNA level determined by RT-PCR, and protein level evaluated by Western blotting analysis. The images are representative of at least three
independent experiments with similar results.
doi:10.1371/journal.pone.0063896.g001
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induce growth and differentiation of mouse neonatal cardiomy-
ocytes [35]. Some experiments were performed treating the cells
with the c-secretase inhibitor, N-3,5-difluorophenyl acetyl-L-
alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT; 5 mM,
stock 5 mM in dymethil sulfoxide, DMSO, 0.1%, Sigma), which
blocks the generation of NICD and hence Notch-1 signaling.
Total RNA Extraction and Reverse Transcription (RT)-PCR
Expression levels of mRNA for RLX family peptide receptor 1
(RXFP1) and Notch-1 were assayed by RT-PCR. Total RNA was
isolated by extraction with TRIzol Reagent (Invitrogen), according
to the manufacturer instructions. One mg of total RNA was reverse
transcribed and amplified with SuperScript One-Step RT-PCR
System (Invitrogen). After cDNA synthesis for 30 min at 55uC, the
samples were pre-denatured for 2 min at 94uC and then subjected
to 40 cycles of PCR performed at 94uC for 15 s, alternating with
55uC for RXFP1, 56uC for Notch-1, and 57uC for GAPDH for
30 s and 72uC for 1 min; the final extension step was performed at
72uC for 5 min. The following mouse gene-specific primers were
used: RXFP1 (NM_ 212452.1), forward 59-ACG AGC TGT CCC
ATC AGT TT-39and reverse 59-ATG TGC TGA CAG AGG
GGT TT-39; Notch-1 (NM_008714.3), forward 59-GTC CCA
CCC ATG ACC ACT AC-39 and reverse 59-CCT GAA GCA
CTG GAA AGG AC-39 and GAPDH (NM_ 008084.2), forward
59-CGTCCCGTAGACAAAATGGT-39 and reverse 59-TCAAT-
GAAGGGGTCGTTGAT -39. GAPDH mRNA was used as
Figure 2. Relaxin attenuates TGF-b1 induced cytoskeletal assembly in NIH/3T3 and primary neonatal cardiac fibroblasts.
Representative confocal immunofluorescence images of (A–D) NIH/3T3 cells stained with TRITC-phalloidin to reveal F-actin and of (E–H) primary
cardiac fibroblasts stained with TRITC-phalloidin (red) and anti-vinculin antibody (green) to detect focal adhesions, cultured for 48 h in the indicated
experimental conditions. I, J) Densitometric analyses of the intensity of F-actin and vinculin fluorescence signals performed on digitized images of
neonatal cardiac fibroblasts. The images are representative of at least three independent experiments with similar results. Significance of differences:
*p,0.05 vs control, up,0.05 vs TGF-b.
doi:10.1371/journal.pone.0063896.g002
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Figure 3. Relaxin reduces a–sma and type I collagen expression in TGF-b1 treated NIH/3T3 and primary neonatal cardiac
fibroblasts. A,B, E,F) Representative confocal immunofluorescence images of NIH/3T3 cells (A,B) and primary cardiac fibroblasts (E, F) cultured in the
indicated experimental conditions and immunostained with antibodies against a–sma (A,E; green) or type I collagen (B, F, red). Nuclei are labeled
(A,E) with propidium iodide (red) or with (B,F) Syto16 (green). The histograms show the corresponding densitometric analyses of the intensity of a–
sma and type I collagen fluorescence signals. C,D) Western blotting analyses of the expression of a–sma and type I collagen proteins in neonatal
cardiac fibroblasts. The densitometric analysis of the bands normalized to GAPDH is reported in the histograms. Data are representative of at least
three independent experiments with similar results. Significance of differences: *p,0.05 vs control, up,0.05 vs TGF-b1.
doi:10.1371/journal.pone.0063896.g003
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Figure 4. Relaxin prevents TGF-b1 induced down regulation of MMP-2 and MMP-9 expression and up-regulation of TIMP-2 in NIH/
3T3 and primary neonatal cardiac fibroblasts. A–C, F–H). Representative confocal immunofluorescence images of NIH/3T3 cells (A–C) and
Relaxin Inhibits Myofibroblast Differentiation
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internal standard. Blank controls, consisting in no template (water),
were performed in each run. PCR products were electrophoresed
on a 2% agarose gel and the ethidium bromide-stained bands were
quantified by densitometric analysis using Scion Image Beta 4.0.2
image analysis program (Scion Corp., Frederick, MD, USA).
GAPDH normalization was performed for each result.
Western Blotting
Cells were resuspended in appropriate volume of ice-cold cell
extraction buffer (10 mM Tris/HCl, pH 7.4, 100 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7,
2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS,
0.5% deoxycholate; Invitrogen) supplemented with 50 ml/ml
protease inhibitor cocktail and 1 mM phenylmethanesulfonyl
fluoride, PMSF (Sigma). Upon centrifugation at 13,000 g for
10 min at 4uC, the supernatants were collected and the total
protein content was quantified using Qubit Protein assay Kit
(Molecular Probes, Eugene, OR) following the manufacturer
instructions. Forty mg of total proteins were electrophoresed on
NuPAGEH 4–12% Bis-Tris Gel (Invitrogen; 200 V, 40 min) and
blotted onto polyvinylidene difluoride (PVDF) membranes (In-
vitrogen; 30 V, 1 h). The membranes were blocked with blocking
solution included in the Western BreezeH Chromogenic Western
Blot Immunodetection Kit (Invitrogen) for 30 min at room
temperature on rotary shaker and incubated overnight at 4uC
with rabbit polyclonal anti relaxin receptor (RXFP; 1:3000,
Immunodiagnostik, Bensheim, Germany), mouse monoclonal anti
-a smooth muscle actin (sma, 1:1000, Abcam, Cambridge, UK),
rabbit polyclonal anti- type I collagen (1:50; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-
metalloprotease (MMP)-2 (1:2000, Abcam), rabbit polyclonal anti-
MMP-9 (1:1000, Abcam), rabbit monoclonal anti-Notch-1
(1:2000; Abcam), goat polyclonal anti-Jagged-1 (1:1000; Santa
Cruz Biotechnology), rabbit monoclonal anti-Smad3 (1:1000; Cell
Signaling Technology, Danvers, MA, USA) and rabbit polyclonal
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
1:1000, Cell Signaling Technology) antibodies, assuming GAPDH
as control invariant protein. Immunodetection was performed as
described in the Western BreezeHChromogenic Immunodetection
protocol (Invitrogen). Densitometric analysis of the bands was
performed using ImageJ software (http://rsbweb.nih.gov/ij) and
the values normalized to GAPDH.
Confocal Immunofluorescence
Cells grown on glass coverslips were fixed with 0.5% buffered
paraformaldehyde (PFA) for 10 min at room temperature. After
permeabilization with cold acetone for 3 min, the fixed cells were
blocked with 0.5% bovine serum albumin (BSA; Sigma) and 3%
glycerol in PBS for 20 min and then incubated overnight at 4uC
with the following primary antibodies: mouse monoclonal anti-
vimentin (1:100, Santa Cruz); mouse monoclonal anti-vinculin
(1:100; Sigma); mouse monoclonal anti-a-sma (1:100, Abcam),
rabbit polyclonal anti- type I collagen (1:50, Santa Cruz); rabbit
polyclonal anti-MMP-2 (1:200; Abcam), rabbit polyclonal anti-
MMP-9 (1:100, Abcam), rabbit monoclonal anti-Notch-1 (1:200,
Abcam), mouse monoclonal anti-tissue inhibitor of metalloprotei-
nase-2 (TIMP-2, 1:20, Abcam), and rabbit polyclonal anti-Hes-1,
a typical Notch-1 transcriptional target gene (1:200, Millipore)
antibodies. Immunoreactions were revealed by specific anti-rabbit
or anti-mouse Alexa Fluor 488-conjugated IgG (1:200; Molecular
Probes) for 1 h at RT. In some experiments, counterstaining was
performed with either TRITC-labeled phalloidin (1:100; Sigma) to
reveal stress fibers, propidium iodide (1:30 for 30 s at RT;
Molecular Probes) or Syto16 (1:1000 for 3 min at RT; Molecular
Probes) to reveal nuclei. Negative controls were carried out by
replacing the primary antibodies with non-immune mouse or
rabbit serum, as appropriate. Negative control experiments were
performed by omitting the primary antibodies. After washing, the
immunolabeled cells were mounted in antifade medium (Biomeda
Gel Mount, Electron Microscopy Sciences, Foster City, CA, USA)
and observed under a confocal Leica TCS SP5 microscope (Leica
Microsystems, Mannheim, Germany) equipped with a HeNe/Ar
laser source for fluorescence measurements. Observations were
performed using a Leica Plan Apo 63X/1.43NA oil immersion
objective. Series of optical sections (102461024 pixels each; pixel
size 204.3 nm) 0.4 mm in thickness were taken through the depth
of the cells at intervals of 0.4 mm. Images were then projected onto
a single ‘extended focus’ image. When needed, a single optical
fluorescent section and DIC images were merged to view the exact
distribution of the immunostaining. Densitometric analyses of the
intensity of F-actin, vinculin, a-sma, MMP-2, MMP-9, TIMP-2,
Notch-ICD, and nuclear Hes-1 fluorescent signals were performed
on digitized images using ImageJ software (http://rsbweb.nih.
gov/ij) in 20 regions of interest (ROI) of 100 mm2 for each confocal
stacks (at least 10).
Silencing of jagged-1 by siRNA. To inhibit the expression
of Jagged-1, short interference RNA duplexes (siRNA) (Santa
Cruz) were used essentially as describred previously [36]. A non-
specific scrambled (SCR) siRNA (Santa Cruz) was used as control.
Primary neonatal cardiac fibroblasts (P1) were transfected using
siRNA trasfection medium (Santa Cruz) with the mixed combi-
nation of Jagged-1 siRNA duplexes or with SCR-siRNA (20 nM)
in serum and antibiotic free medium. After 5 h, transfected cells
were cultured in fresh medium containing FBS for additional 24 h
(T0), and then shifted in DMEM with 2% FBS and penicillin/
streptomycin, stimulated or not with TGF-b1 (2 ng/ml) in the
presence or absence of RLX, for 24 h. Specific knock-down of
Jagged-1 was evaluated by confocal immunofluorescence (not
shown) and Western blotting. The efficiency of transfection was
estimated to be approximately 70%.
Immunoprecipitation
The cells were lysed as reported previously [37]. One mg of
whole cell extract was pre-cleared by Protein A/G Plus-Agarose
(Santa Cruz Biotechnology) for 1 h at 4uC. After centrifugation,
the supernatants were collected in tubes and incubated overnight
at 4uC with monoclonal rabbit anti-Smad3 antibody diluted 1:100
(Cell Signaling Technology), gently inverting the tubes. Then the
samples were re-incubated with Protein A/G Plus-Agarose for 2 h
at 4uC and precipitated by centrifugation. Complexes were
subjected to electrophoresis and blotted with mouse monoclonal
anti-phospho-tyrosine antibody (1:1000; Santa Cruz Biotechnol-
primary neonatal cardiac fibroblasts (F–H) cultured in the indicated experimental conditions and immunostained with antibodies against MMP-2 (A,F;
cyan), MMP-9 (B,G; green) or TIMP-2 (C,H, green). In B and G the nuclei are labeled in red with propidium iodide. The histograms show the
corresponding densitometric analyses of the intensity of MMP-2, MMP-9 and TIMP-2 fluorescence signals. D–E) Western blotting analyses of the
expression of (D) MMP-2, and (E) MMP-9 proteins in neonatal cardiac fibroblasts. In the histograms the densitometric analyses of the bands
normalized to GAPDH are reported. Data are representative of at least three independent experiments with similar results. Significance of differences:
*p,0.05 vs control, up,0.05 vs TGF-b1.
doi:10.1371/journal.pone.0063896.g004
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ogy) and then re-probed with rabbit monoclonal anti-Smad3
antibody (1:1000; Cell Signaling Technology).
Statistical Analysis
Data were reported as mean 6 SEM. Unless otherwise stated,
statistical significance was determined by one-way ANOVA and
Figure 5. Relaxin prevents the TGF-b1-induced down-regulation of Notch-1 pathway in primary neonatal cardiac fibroblasts. A) RT-
PCR of Notch-1 expression. B,C) Western blotting analysis of activated intracellular form of Notch-1 (Notch-ICD, B) ) and of Notch-1 ligand, Jagged-
1(C). The densitometric analyses of the bands normalized to GAPDH are reported in the histograms. D) Confocal immunofluorescence analysis of
Notch-1 (green) and Hes-1 (cyan) expression. For the analysis of Notch-1, the cells were stained with a specific antibody recognizing both the
membrane Notch-1 receptor and its activated intracellular form, Notch-ICD. Densitometric analyses of Notch-ICD and Hes-1 fluorescent signals are
reported in the corresponding histogram. Significance of differences: *p,0.05 vs control, up,0.05 vs TGF-b1.
doi:10.1371/journal.pone.0063896.g005
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Newman-Keuls multiple comparison test or Student’s t test. A p
value#0.05 was considered significant. Calculations were per-
formed using GraphPad Prism software (GraphPad, San Diego,
CA, USA).
Results
Relaxin Inhibits TGF-b-stimulated Cardiac Fibroblast-
myofibroblast Transition
Neonatal cardiac stromal cells at P1 culture passage were first
characterized morphologically and immunophenotypically: they
showed the typical features of fibroblasts with elongated polygonal
or spindle shape, large ovoid nuclei (Fig. 1A) and strong vimentin
immunoreactivity (Fig. 1B). Then, the expression of RXFP by
NIH/3T3 fibroblasts and neonatal cardiac stromal cells was
ascertained by RT-PCR and Western blotting (Fig. 1C). On these
cells, we evaluated the effects of RLX on fibroblast-myofibroblast
transition. To this aim, NIH/3T3 fibroblasts and neonatal cardiac
stromal cells were grown in low serum medium with a added with
TGF-b1 (2 ng/ml), a well-known pro-fibrotic factor, in the
absence or presence of RLX (100 ng/ml) for 48 h. Confocal
immunofluorescence analysis showed that TGF-b1 induced a
prominent cytoskeletal rearrangement, consisting in the formation
of robust stress fibres and focal adhesion sites (Fig. 2). As judged by
confocal immunofluorescence and Western blotting analyses, this
effect was associated with an increase in both a-sma, a marker of
myofibroblasts, and type I collagen expression (Fig. 3). In
particular, a-sma was mainly localized along the stress fibres
(Fig. 3A,E), whereas type I collagen was mainly distributed
throughout the cytoplasm in both NIH/3T3 and cardiac
fibroblasts (Fig. 3 B,F). We also found that the levels of MMP-2
and MMP-9 decreased in TGF-b1-stimulated cells (Fig. 4A,B, D–
G); these enzymes showed distinct cellular distributions, being
MMP-2 mainly located inside the cytoplasm (Fig. 4 A,F) and
MMP-9 concentrated along cytoskeletal filaments (Fig. 4 B,G).
Moreover, the expression of TIMP-2 was significantly increased in
the stimulated NIH/3T3 cells (Fig. 4 C) and cardiac fibroblasts
(Fig. 4H), in agreement with data showing that high TIMP-2 levels
have a potent inhibitory action on MMP activation [38].
RLX alone did not affect the morphological pattern of the
unstimulated NIH/3T3 fibroblasts and cardiac stromal cells,
whose cytoskeletal apparatus, as well as the expression of a-sma,
type I collagen, MMP-2, MMP-9 and TIMP-2, appeared
unmodified by RLX addition as compared with the unstimulated
control cells (Figs. 2–4). On the other hand, RLX was able to
strongly reduce the phenotypical changes induced by TGF-b1,
based on the findings that it was able to: i) inhibit stress fiber
assembly and re-distribution of vinculin to focal adhesion sites
(Fig. 2); ii) prevent the up-regulation of a-sma (Fig. 3A,C, E) and
type I collagen (Fig. 3 B,D,F); iii) reduce the down regulation of
MMP-2 and MMP-9 (Fig. 4 A,B, D–G) and, iv) reduce the
expression of TIMP-2 (Fig. 4C,H), in TGF-b1-stimulated cells.
Figure 6. RLX and Notch-1 negatively regulates TGF-b1-induced fibroblast-myofibroblast transition in cardiac fibroblasts. Neonatal
cardiac fibroblasts were cultured for 48 h and treated as indicated. A) Western blotting analysis of NICD expression in the absence (control) or
presence of DAPT (5 mM) a pharmacological c-secretase inhibitor, used to block the generation of NICD. B) Western Blotting analysis of a–sma and
MMP-2 expression in the cells treated with DAPT. C) Representative confocal immunofluorescence images cardiac fibroblasts treated with DAPT, fixed
and stained with antibodies against a–sma (green). Nuclei are marked in red with propidium iodide. D) Western blotting analysis of Jagged-1
expression in control cells, cells transfected with non specific scrambled-siRNA (SCR-siRNA) or silenced for the expression of Notch-1 ligand, Jagged-1,
by specific Jagged-1 siRNA (Jagged-1 siRNA). E) Western Blotting analysis of a–sma in Jagged-1 silenced cells. F) Representative confocal
immunofluorescence images cardiac fibroblasts silenced for Jagged-1 expression, fixed and stained with antibodies against a–sma (green). Nuclei are
marked in red with propidium iodide. The densitometric analyses of the bands normalized to GAPDH are reported in histograms in A–E; the
densitometric analyses a–sma fluorescent signal are shown in the histograms in and C, F. Significance of differences: *p,0.05 vs control, dp,0.05 vs
SCR-siRNA, up,0.05 vs TGF-b1, #p,0.05 vs TGF-b1+ RLX.
doi:10.1371/journal.pone.0063896.g006
Figure 7. RLX and Notch-1 negatively regulates TGF-b1 signaling in primary neonatal cardiac fibroblasts. (A) Western blotting analysis
of Smad3 expression and (B) phosphorylation (performed on the immunoprecipitated Smad3 proteins) in cardiac fibroblasts cultured for 48 h in the
indicated experimental conditions. Data are representative of at least three independent experiments. Histograms show the densitometric analyses of
the bands normalized to (A) GAPDH and (B) total Smad3. Significance of differences: *p,0.05 vs TGF-b1.
doi:10.1371/journal.pone.0063896.g007
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Notch-1 Pathway is Involved in RLX-mediated Inhibition
of Cardiac Fibroblast-myofibroblast Transition
To investigate the molecular mechanisms underlying the
inhibitory effect of RLX on TGF-b1-induced fibroblast-myofibro-
blast transition, we next investigated the involvement of Notch-1
signaling, which has been implicated in the process of tissue
fibrosis [26–28]. By RT-PCR, Notch-1 mRNA expression was
detected in NIH/3T3 cells (data not shown) and neonatal cardiac
stromal cells after 24 h and 48 h of culture (Fig. 5A); this
expression was dramatically reduced by the administration of
TGF-b1 as compared with the unstimulated control cells (Fig. 5A).
As demonstrated by Western blotting, TGF-b1 also caused a
significant decrease of the levels of NICD, the intracellular form of
activated Notch-1 as well as of Notch-1 ligand, Jagged-1 (Fig. 5B,
C). By confocal immunofluorescence, using a specific antiserum
recognizing both Notch-1 receptor and NICD, we confirmed the
reduced expression of both Notch-1 receptor at the plasma
membrane and NICD within the cytoplasm and nucleus in the
TGF-b1-stimulated cells as compared with the unstimulated
controls (Fig. 5D). Moreover, in keeping with the reduced
expression and activation of Notch-1, the expression of Hes-1, a
canonical Notch-1 transcriptional target gene, was also signifi-
cantly down-regulated by TGF-b1 (Fig. 5D), confirming the
notion of a functional antagonisms between TGF-b1 and Notch-1
in cardiac fibroblasts. The administration of RLX to unstimulated
fibroblasts did not affect the basal expression of Notch-1 and
Jagged-1, and induced a slight increase in the levels of Hes-1 (Fig. 5
A–D). Interestingly, the hormone prevented the reduction of
Notch-1, Jagged-1 and Hes-1 induced by TGF-b1 (Fig. 5 A–D).
Furthermore, the pharmacological inhibition of endogenous
Notch-1 signaling by DAPT (5 mM) which blocks the generation
of NICD (Fig. 6A), as well as the silencing of Notch-1 ligand,
Jagged-1 (Fig. 6D), were both capable of potentiating TGF-b1-
induced generation of myofibroblasts, as judged by increased a–
sma (Fig. 6 B,C,E,F) and reduced MMP-2 (Fig. 6B) in the treated
cardiac fibroblasts. As expected, the treatment with DAPT and
Jagged-1-siRNA also abrogated the inhibitory effects of RLX on
TGF-b1-induced fibroblast-myofibroblast transition
(Fig. 6 B,C,E,F).
Finally, we demonstrated that RLX and Notch-1 exerted their
antifibrotic effects interfering with the TGF-b1-mediated intracel-
lular signaling. In fact, the addition of RLX to TGF-b1-treated
cardiac fibroblasts caused a marked decrease in phosphorylated
Smad3 (pSmad3), the TGF-b1 downstream signaling molecule,
without modifying its expression (Fig. 7). Conversely, the addition
of DAPT to TGF-b1-stimulated cells increased the levels of
pSmad3 and prevented the inhibitory effects of RLX (Fig. 7).
Taken together, these findings suggest that Notch-1 signaling
can negatively regulate TGF-b1/Smad3-mediated fibroblast-
myofibroblast transition and that RLX could exert its anti-fibrotic
action through the up-regulation of this pathway.
Discussion
The balance between collagen synthesis and degradation after
tissue injury, as occurs upon myocardial infarction, is regulated by
myofibroblasts. These cells mainly originate from cardiac fibro-
blasts [39,40], andrespond to mechanical stretch, ischemia,
autocrine and paracrine factors - such as angiotensin II, TGF-b1
and pro-inflammatory cytokines - by increasing synthesis and
deposition of ECM proteins which replace the necrotic myocar-
dium with a scar. The most typical feature of these cells is de novo
formation and deployment of stress fibers, the expression of
smooth muscle genes, such as a-sma and collagen synthesis and
deposition. Although myofibroblasts are required to stabilize the
infarcted area and promote scar tissue contraction, their persis-
tence can contribute to abnormal myocardial stiffness and
impairment of ventricular function. Along this line, identification
of the factors and mechanisms capable of preventing myofibroblast
generation and defining their molecular targets appears a key step
for the design of therapeutic strategies aimed at inhibiting
excessive left ventricular stiffness after myocardial infarction. In
the present study, we have demonstrated that RLX can inhibit
cardiac fibroblast-myofibroblast transition in vitro by interfering
with TGF-b1 signaling. This new achievement confirms and
extends the knowledge on the anti-fibrotic action of this hormone
and on its beneficial actions in the cardiovascular system under
pathological conditions [1,2,4–6]. In particular, our results have
shown that RLX, administered to TGF-b1-stimulated NIH/3T3
fibroblasts and cardiac stromal cells, down-regulates multiple
processes involved in adverse cardiac remodeling, causing
inhibition of stress fibers and formation of focal adhesion sites
which play a key role in enhancing the promoter activity of
collagen genes [41], reduction of a-sma and type I collagen
expression, and up-regulation of MMP-2 and MMP-9. In turn,
MMPs can degrade collagen and other ECM proteins and
contribute to tissue remodeling. It is well accepted that ECM
homeostasis is also dependent on a fine coordination between
these proteolytic enzymes and their specific tissue inhibitors
(TIMPs) [42,43]. In a such a view our data showing the ability of
RLX to up-regulate MMPs and concomitantly reduce the
expression of TIMP-2 in TGF-b1-stimulated cardiac fibroblasts
further suggest the central role played by this hormone in
promoting ECM turnover and clearance [1,2].
These effects were likely mediated through the interaction of
RLX with its specific receptor RXFP1, which is fairly expressed by
both NIH/3T3 fibroblasts and cardiac stromal cells and is known
to play a major role in the modulation of RLX-induced tissue
remodeling [16,44,45].
TGF-b1 signals through trans-membrane receptors, which
activate Smad2/3 phosphorylation: in turn, pSmad2/3 complex
translocates into the nucleus where they induce the expression of
pro-fibrotic target genes [46,47]. Several distinct mechanisms have
been postulated or demonstrated to be involved in RLX-mediated
inhibition of TGF-b1/Smad axis including the PI3K-Akt and
NOS-NO-cGMP cascades [18,44,48]. The results of the present
study expand the list of the possible mechanisms underlying the
anti-fibrotic action of RLX, demonstrating for the first time that
this hormone also acts through Notch-1 up-regulation and
activation to inhibit myofibroblast generation and up-regulate
MMP expression and activity in NIH/3T3 fibroblasts and cardiac
stromal cells. Indeed, we observed that RLX prevented the
reduction of Notch-1 expression induced by TGF-b1, and that the
pharmacological inhibition of endogenous Notch-1 signaling by
DAPT blocked the effects of RLX on inhibition of the fibroblast-
myofibroblast transition, the reduction of MMP levels and the
down-regulation of pSmad3 in response to TGF-b1 stimulation.
The importance of Notch-1 in cardiac myofibroblast generation is
consistent with previous in vitro observations showing that down-
regulation of this pathway in neonatal rat cardiac fibroblasts is
necessary for their differentiation into a-sma-positive myofibro-
blasts [25] and with a recent study on an in vivo model of mouse
cardiac hypertrophy underscoring its potential significance in
cardiac fibrotic response. In particular, it has been demonstrated
that Notch-1 controls the balance between fibrotic and regener-
ative repair in the adult heart, inhibiting myofibroblast generation
and promoting mobilization and expansion of cardiac precursors
[49].
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Previous reports indicate that Notch-1 can interfere with TGF-
b1 signaling through a direct interaction of NICD and Smad3
[50–52]. This cross-talk may lead to transcriptional cooperation or
antagonism, mostly depending on the cell context [46,53]. Along
this line, our observation that Notch-1 is required for RLX-
mediated inhibition of the phenotypic switch of cardiac fibroblasts
to myofibroblasts offers novel clues to the complex molecular
circuitry, which mediates the effects of RLX on ECM turnover. It
is conceivable that Notch-1 may cross-talk with other major
pathways to inhibit TGF-b1-mediated cardiac fibrosis. Consis-
tently, the recent findings that iNOS, a major signaling molecules
of RLX action [54], induces Notch-1 expression and facilitates its
signaling [55], imply a mechanistic relationship between these two
proteins. Further studies assessing how iNOS and Notch-1
pathways are interlinked and cooperate to mediate the effects of
RLX on cardiac fibroblasts will be required to further clarify the
mechanisms of the anti-fibrotic action of this hormone and better
define its therapeutic range in fibrotic diseases.
In conclusion, the present study offers new evidence that RLX,
via the up-regulation of Notch-1 signaling, inhibits TGF-b1/
pSmad axis and antagonizes the effects of TGF-b1 on cardiac
fibroblast-myofibroblast transition. These findings may provide
promising prospects for the causative treatment of patients
suffering for myocardial fibrosis using RLX or RXFP1agonists.
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